Biosimilar Insulin and Costs: What Can We Expect?

Biosimilar Insulin and Costs: What Can We Expect?

Item
http://www.wikidata.org/entity/Q36638889
If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?)Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials.The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.Production costs and potential prices for biosimilars of human insulin and insulin analogues
P2860

Biosimilar Insulin and Costs: What Can We Expect?

Item
http://www.wikidata.org/entity/Q36638889
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Biosimilar Insulin and Costs: What Can We Expect?
@ast
Biosimilar Insulin and Costs: What Can We Expect?
@en
type
label
Biosimilar Insulin and Costs: What Can We Expect?
@ast
Biosimilar Insulin and Costs: What Can We Expect?
@en
prefLabel
Biosimilar Insulin and Costs: What Can We Expect?
@ast
Biosimilar Insulin and Costs: What Can We Expect?
@en
P1433
P1476
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Biosimilar Insulin and Costs: What Can We Expect?
@en
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932